Nanoparticle Tumor Accumulation
Nanoparticle Tumor Accumulation - Related Videos
09:00
Spatial Measurements of Perfusion, Interstitial Fluid Pressure and Liposomes Accumulation in Solid Tumors
0 Views •
Cited by 6 •
2016
The heterogeneous intra-tumoral accumulation of liposomes has been linked to an abnormal tumor microenvironment. Herein methods are presented to measure tumor microcirculation by perfusion imaging and elevated interstitial fluid pressure (IFP) using an image-guided robotic system. Measurements are compared to the intra-tumoral accumulation of liposomes, determined using volumetric micro-CT imaging.
14:04
Viral Nanoparticles for In vivo Tumor Imaging
0 Views •
Cited by 45 •
2012
Plant viral nanoparticles (VNPs) are promising platforms for applications in biomedicine. Here, we describe the procedures for plant VNP propagation, purification, characterization, and bioconjugation. Finally, we show the application of VNPs for tumor homing and imaging using a mouse xenograft model and fluorescence imaging.
08:04
Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging
0 Views •
Cited by 51 •
2011
We present a novel approach to quantify nanoparticle localization in the vasculature of human xenografted tumors using dynamic, real-time intravital imaging in an avian embryo model.
01:28
Focused Ultrasound-Enhanced Nanoparticle Delivery in a Mouse Model for Tumor Therapy
0 Views •
2025
Begin with an anesthetized tumor-bearing mouse and shave its head.Place it in an MRI scanner integrated with the focused ultrasound system.The initial MRI scan locates the brain tumor and nearby blood vessels.Inject a contrast agent intravenously, then administer fluorescently labeled nanoparticles coated onto gas-filled microbubbles.The contrast agent and microbubbles circulate and reach the brain.Apply focused ultrasound waves to the tumor site.The ultrasound causes the microbubbles to expand...
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
FAQs
Leaky tumor blood vessels and impaired lymphatic drainage create conditions that favor nanoparticle retention. Passive transport depends on these structural differences between tumor and healthy tissue rather than on a binding ligand. The resulting distribution can increase local exposure to an imaging agent or therapeutic, although heterogeneous tumor architecture may make accumulation uneven.
Size and surface properties are important variables because they influence how carriers circulate, move through tumor tissue, and are taken up by cells. These factors should therefore be considered together rather than independently when designing a nanoparticle system. Their effects are especially significant when tumor architecture varies across a lesion or between tumors.
Circulation affects the time and opportunity nanoparticles have to reach tumor tissue. It is therefore considered alongside size, surface properties, and cellular uptake when explaining carrier distribution. Evaluating these characteristics helps clarify why two nanoparticle systems intended for the same tumor may produce different accumulation patterns and different potential for imaging or therapeutic delivery.
A study of nanoparticle tumor accumulation can connect carrier design with distribution and uptake. Researchers may characterize nanoparticle size and surface properties, consider circulation, and examine cellular uptake in tumor tissue. They can then assess whether the system supports delivery of an imaging agent or therapeutic while accounting for heterogeneous architecture that may affect observed distribution.
Brain tumors add a major distribution constraint because the blood-brain barrier can restrict nanoparticle and drug access. Consequently, accumulation in a brain tumor cannot be interpreted solely from general tumor vascular features. Investigators must consider barrier limitations together with heterogeneous architecture when assessing whether a carrier can support diagnosis or treatment in gliomas and other central nervous system cancers.
The approach supports two broad outcomes: concentrating imaging agents for tumor visualization and delivering therapeutics while limiting exposure to healthy cells. In neuroscience, this makes accumulation relevant to glioma and other central nervous system cancers. It also provides a framework for comparing passive transport with ligand-based targeting when planning more precise diagnostic or treatment strategies.